Overexpression of human epidermal growth factor receptor 2 (HER2) has been demonstrated in 20%–30% of ovarian cancers, particularly in cancers with poor prognosis (Lanitis et al., 2012; Iqbal and Iqbal, 2014). This evidence concerns the gene ERBB2 and ovarian cancer.